Samsung Biologics Co Ltd
KRX:207940
Intrinsic Value
SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. [ Read More ]
The intrinsic value of one Samsung Biologics Co Ltd stock under the Base Case scenario is 415 278.78 KRW. Compared to the current market price of 833 000 KRW, Samsung Biologics Co Ltd is Overvalued by 50%.
Valuation Backtest
Samsung Biologics Co Ltd
Run backtest to discover the historical profit from buying and selling Samsung Biologics Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Samsung Biologics Co Ltd
Current Assets | 5.4T |
Cash & Short-Term Investments | 1.8T |
Receivables | 895.4B |
Other Current Assets | 2.7T |
Non-Current Assets | 10.5T |
Long-Term Investments | 39B |
PP&E | 4.3T |
Intangibles | 5.9T |
Other Non-Current Assets | 291.8B |
Current Liabilities | 4.1T |
Accounts Payable | 164.5B |
Accrued Liabilities | 284.3B |
Short-Term Debt | 509.5B |
Other Current Liabilities | 3.1T |
Non-Current Liabilities | 2.2T |
Long-Term Debt | 487.6B |
Other Non-Current Liabilities | 1.7T |
Earnings Waterfall
Samsung Biologics Co Ltd
Revenue
|
3.7T
KRW
|
Cost of Revenue
|
-1.9T
KRW
|
Gross Profit
|
1.8T
KRW
|
Operating Expenses
|
-689.1B
KRW
|
Operating Income
|
1.1T
KRW
|
Other Expenses
|
-256B
KRW
|
Net Income
|
857.7B
KRW
|
Free Cash Flow Analysis
Samsung Biologics Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Samsung Biologics Co Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Score
Samsung Biologics Co Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Samsung Biologics Co Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Score
Samsung Biologics Co Ltd's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Samsung Biologics Co Ltd
According to Wall Street analysts, the average 1-year price target for Samsung Biologics Co Ltd is 1 036 354.03 KRW with a low forecast of 757 500 KRW and a high forecast of 1 312 500 KRW.
Shareholder Return
Price
Samsung Biologics Co Ltd
Average Annual Return | 32.25% |
Standard Deviation of Annual Returns | 44.32% |
Max Drawdown | -34% |
Market Capitalization | 59.3T KRW |
Shares Outstanding | 71 174 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. The company is headquartered in Incheon, Incheon. The company went IPO on 2016-11-10. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. The company also provides cell line development and process development services. The firm distributes its products in domestic and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Samsung Biologics Co Ltd stock under the Base Case scenario is 415 278.78 KRW.
Compared to the current market price of 833 000 KRW, Samsung Biologics Co Ltd is Overvalued by 50%.